Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037

被引：0

作者：

Hamid, O. ^{[1
]}

Gajewski, T. F. ^{[2
,3
]}

Frankel, A. E. ^{[4
]}

Bauer, T. M. ^{[5
]}

Olszanski, A. J. ^{[6
]}

Luke, J. J. ^{[7
]}

Balmanoukian, A. S. ^{[1
]}

Schmidt, E. V. ^{[8
]}

Sharkey, B. ^{[9
]}

Maleski, J. ^{[9
]}

Jones, M. J. ^{[9
]}

Gangadhar, T. C. ^{[10
]}

机构：

[1] Angeles Clin & Res Inst, Res, Los Angeles, CA USA

[2] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA

[3] Univ Chicago, Dept Med, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA

[4] Univ Texas Southwestern Med Ctr Dallas, Internal Med, Dallas, TX 75390 USA

[5] Sarah Cannon Res Inst Tennessee Oncol, Drug Dev Unit, Nashville, TN USA

[6] Fox Chase Canc Ctr, Dept Med Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[7] Univ Chicago, Hematol Oncol, Chicago, IL 60637 USA

[8] Merck & Co Inc, Oncol Clin Res, Kenilworth, NJ USA

[9] Incyte Corp, Drug Dev, Wilmington, DE USA

[10] Univ Penn, Abramson Canc Ctr, Hematol Oncol Div, Med, Philadelphia, PA 19104 USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1214O

引用

页数：2

共 50 条

[31] A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma
Silk, Ann W.
Curti, Brendan
Bryan, Jennifer
Saunders, Tracie
Shih, Weichung
Kane, Michael P.
Hannon, Phoebe
Fountain, Christopher
Felcher, Jessica
Zloza, Andrew
Kaufman, Howard L.
Mehnert, Janice M.
McDermott, David F.
FRONTIERS IN ONCOLOGY, 2023, 13
[32] Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
Frenel, Jean-Sebastien
Le Tourneau, Christophe
O'Neil, Bert
Ott, Patrick A.
Piha-Paul, Sarina A.
Gomez-Roca, Carlos
van Brummelen, Emilie M. J.
Rugo, Hope S.
Thomas, Shari
Saraf, Sanatan
Rangwala, Reshma
Varga, Andrea
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) : 4035 - +
[33] Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
Im, Seock-Ah
Cortes, Javier
Cescon, David W.
Yusof, Mastura Md
Iwata, Hiroji
Masuda, Norikazu
Takano, Toshimi
Huang, Chiun-Sheng
Chung, Chi-Feng
Tsugawa, Koichiro
Park, Yeon Hee
Matsumoto, Koji
Inoue, Kenichi
Kwong, Ava
Loi, Sherene
Fu, Wei
Pan, Wilbur
Karantza, Vassiliki
Rugo, Hope S.
Schmid, Peter
NPJ BREAST CANCER, 2024, 10 (01)
[34] Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
Matulonis, U. A.
Shapira-Frommer, R.
Santin, A. D.
Lisyanskaya, A. S.
Pignata, S.
Vergote, I
Raspagliesi, F.
Sonke, G. S.
Birrer, M.
Provencher, D. M.
Sehouli, J.
Colombo, N.
Gonzalez-Martin, A.
Oaknin, A.
Ottevanger, P. B.
Rudaitis, V
Katchar, K.
Wu, H.
Keefe, S.
Ruman, J.
Ledermann, J. A.
ANNALS OF ONCOLOGY, 2019, 30 (07) : 1080 - 1087
[35] Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
Yap, Timothy A.
Nakagawa, Kazuhiko
Fujimoto, Nobukazu
Kuribayashi, Kozo
Guren, Tormod Kyrre
Calabro, Luana
Shapira-Frommer, Ronnie
Gao, Bo
Kao, Steven
Matos, Ignacio
Planchard, David
Chatterjee, Arkendu
Jin, Fan
Norwood, Kevin
Kindler, Hedy L.
LANCET RESPIRATORY MEDICINE, 2021, 9 (06): : 613 - 621
[36] Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
Makker, Vicky
Colombo, Nicoletta
Herraez, Antonio Casado
Monk, Bradley J.
Mackay, Helen
Santin, Alessandro D.
Miller, David S.
Moore, Richard G.
Baron-Hay, Sally
Ray-Coquard, Isabelle
Ushijima, Kimio
Yonemori, Kan
Kim, Yong Man
Guerra Alia, Eva M.
Sanli, Ulus A.
Bird, Steven
Orlowski, Robert
McKenzie, Jodi
Okpara, Chinyere
Barresi, Gianmaria
Lorusso, Domenica
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16) : 2904 - +
[37] INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)
Fujiwara, Yutaka
Shitara, Kohei
Shimizu, Toshio
Yonemori, Kan
Matsubara, Nobuaki
Ohno, Izumi
Kogawa, Takahiro
Naito, Yoichi
Leopold, Lance
Sasahara, Kahori
Yatsuzuka, Naoyoshi
Takami, Tomoko
Shimamoto, Takashi
Yamamoto, Noboru
Doi, Toshihiko
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[38] Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Shitara, Kohei
Van Cutsem, Eric
Bang, Yung-Jue
Fuchs, Charles
Wyrwicz, Lucjan
Lee, Keun-Wook
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol
Lee, Jeeyun
Castro, Hugo Raul
Mansoor, Wasat
Braghiroli, Maria Ignez
Karaseva, Nina
Caglevic, Christian
Villanueva, Luis
Goekkurt, Eray
Satake, Hironaga
Enzinger, Peter
Alsina, Maria
Benson, Al
Chao, Joseph
Ko, Andrew H.
Wainberg, Zev A.
Kher, Uma
Shah, Sukrut
Kang, S. Peter
Tabernero, Josep
JAMA ONCOLOGY, 2020, 6 (10) : 1571 - 1580
[39] Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma
Yokota, Kenji
Takenouchi, Tatsuya
Fujisawa, Yasuhiro
Fukushima, Satoshi
Uchi, Hiroshi
Inozume, Takashi
Kiyohara, Yoshio
Uhara, Hisashi
Nakagawa, Kazuhiko
Furukawa, Hiroshi
Han, Shirong
Watanabe, Masaru
Noguchi, Kazuo
Yamazaki, Naoya
JOURNAL OF DERMATOLOGY, 2024, 51 (05): : 632 - 642
[40] KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma
Atkins, Michael B.
Carlino, Matteo S.
Hill, Andrew G.
McNeil, Catriona M.
Long, Georgina V.
Atkinson, Victoria
Cebon, Jonathan S.
Jameson, Michael B.
Hwu, Wen-Jen
Thompson, John A.
Anderson, James
Moreno, Blanca Homet
Ibrahim, Nageatte
Ribas, Antoni
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →